Dear {{first_name|there}},
Happy Friday and your weekly dose of doom is here!
Doom Signals is your weekly briefing on the headlines, market shifts, and warning signs proving why CPG is a burning platform.
Canada Retaliates on C$27.6B of US Imports — Cosmetics and Plastics, Sept 8 ‘26
Canada announced counter-tariffs of 15–50% on 700+ US products covering C$27.6B — a dollar-for-dollar response to US Section 338 tariffs effective August 22. Simultaneously, the Canadian list explicitly targets cosmetics and plastics.
Why structural: When a trade war targets beauty inputs as deliberate leverage, the cost structure of beauty CPG has become a geopolitical instrument — the supply chain for every shampoo bottle and plastic tube crossing the US-Canada border is now a trade-policy variable on both sides.
Private Label's Power Play: Mass Retail Sets Fire to the Beauty Partnership.
Circana data shows store brands reached 23.8% unit market share in H1 2026, outpacing national brands in unit growth across every department. Simultaneously, Target ended its five-year Ulta partnership, launching "Beauty Studio" in ~600 stores with 1,600 products and 90 brands — two-thirds new to Target — assuming full margin ownership of the space Ulta occupied.
Why structural: Private label at 23.8% unit share is not a cycle — it is a rearchitecture of the shelf. When mass retailers curate their own prestige shelves instead of outsourcing, the partnership model has been eliminated and the retailer is now the competitor, not the channel.
Big Beauty Split: Is Acquisition The Only Play Left? — L'Oréal +6.5%, e.l.f. +36%, Coty –7%
L'Oréal grew 6.5% to €23.77B, led by hair care (+15.6%). e.l.f.'s 36% growth is entirely rhode — e.l.f.'s own core line was flat for a second straight quarter, same earnings call. Coty fell 7%.
Why structural: When R&D timelines can't keep pace with the shelf, acquisition becomes the only on-ramp to relevance — e.l.f. bought rhode because its core couldn't build what's next. L'Oréal proves the R&D engine still works, if it's aimed at a real shift; Coty proves what happens when neither acquisition nor R&D fires: margin loss.
Biotech Is the New Beauty Supply Chain; Proya AI-Compresses PDRN Timelines; Exosome Reviews +229%
"Chinese consumers now compare cosmetics against Botox, GLP-1s, and cosmetic surgery, demanding clinical proof of results," says Yatsen's CSO. Yatsen used AI to compress a two-year PDRN development cycle into six months, narrowing 50+ ingredient candidates to three in a single week. Simultaneously, exosome reviews on Olive Young jumped 229% over six months.
Why structural: When consumers cite injection names in retail reviews, the purchase has migrated from brand trust to clinical credential — brands without the infrastructure to innovate ahead of the trend curve will lose market share as consumers move away from traditional products.
The Packaging Squeeze: Dow Hiked Prices 30% and Volume Fell — Beauty Pays the Difference
Dow Q2 Packaging & Specialty Plastics prices rose 30% year-over-year while volume fell 4%. Simultaneously, MEG — the primary PET feedstock for shampoo bottles, lotion tubes, and aerosol cans — surged nearly 8% in the week ending August 21, with supply tightening through August and September on reduced Middle East exports .
Why structural: When the world's largest packaging supplier raises prices 30% while volume contracts, the increase isn't demand-driven — it's margin capture from downstream. Every beauty CPG company filling a plastic tube is now paying Dow's price, not the market's. The input-cost floor has risen faster than the consumer's willingness to pay.